

Supplemental Figure 1: Distribution of GFP::GBDwsp-1 fluorescent lifetimes in embryos expressing either GFP::GBDwsp-1 alone or co-expressed with either mCHERRY::CDC-42(T17N) or mCHERRY::CDC-42(Q61L)

The fluorescence lifetime of GFP::GBDwsp-1 (expressed from one genetic copy; GFP-only cross products) was statistically indistinguishable in embryos expressing GFP::GBDwsp-1 alone (GFP only cross products) vs coexpressed with mCHERRY::CDC-42(T17N) (WH432xWH517, $p>0.8$), but was significantly shortened when coexpressed with CDC-42(Q61L) (WH423xWH517, $p<0.01$) and was significantly lengthened when expressed from 2x genetic dose (WH517 GFP only, $p<0.02$).

Supplemental Figure 2: Localization of GFP-tagged CDC-42 and two of its mutant forms

Timeseries of the localization of GFP-fusions of CDC-42, the constitutively inactive mutant T17N and the constitutively active mutant Q61L in embryos from polarization to 2-cell stage. Arrowheads indicate polarized enrichment of cortical signal. Scale bar is 10 μ m.

Supplemental Figure 3: Localization of GFP-tagged CGEF-1A

Timeseries of the localization of a GFP-fused CGEF-1A. There is enrichment of the nucleoplasm and a subtle enrichment at the cortex in Phase II. Scale bar is 10 μ m.

Supplemental Figure 4: Observed maximum speeds of GFP::NMY-2-labeled cortical regions during Phase I

The flow rates of five of the fastest moving GFP::NMY-2 puncta were measured from kymographs of timeseries collected from embryos of the described genotype. Error bars represent the observed SEM and are absent in conditions with a single usable embryo. “*” indicates that the measured speeds were statistically significantly different from those of the wild type at $p<0.05$.

Supplemental Figure 5: RHO-1 and CDC-42 pathway components are required to recruit GFP::NMY-2 to the cortex in distinct phases

Embryos expressing GFP::NMY-2 in the early embryo. In the wild type, GFP::NMY-2 localizes to the cortex in distinct morphological distributions in Phases I and II. The robust myosin foci observed in Phase I depend upon ECT-2, RHO-1 and LET-502. The robust, diffuse, polar distribution of smaller myosin puncta in Phase II depends upon CGEF-1, CDC-42 and MRCK-1. Disruption of either pathway does not abolish the recruitment by the other, and disruption of both pathways disrupts both recruitment patterns. Double disruptions tested include *mrck-1(ok586); let-502(frNAi)*, *mrck-1(ok586); ect-2(frNAi)*, *cdc-42(frNAi); let-502(frNAi)*, *cdc-42(frNAi); rho-1(frNAi)*, *cdc-42(frNAi); ect-2(frNAi)*, *ect-2(frNAi); cgef-1(gk261)*; *let-502(frNAi); cgef-1(gk261)*; *rho-1(frNAi)*, and *cgef-1(gk261); ect-2(frNAi)*. All these double disrupted embryos exhibited defects in both Phase I and Phase II cortical myosin recruitment. *mrck-1(ok586)* embryos exhibited more severe phenotypes than did *mrck-1(frNAi)* embryos. The images from Figure 6 are duplicated here for completeness. Scale bar is 10 μ m.

Movie 1: Time-lapse movie of GFP::GBDwsp-1 expressed in a *control(frNAi)* embryo. Movie plays at 60x real time.

Movie 2: Time-lapse movie of GFP::GBDwsp-1 expressed in a *cdc-42(frNAi)* embryo. Movie plays at 60x real time.

Movie 3: Time-lapse movie of GFP::GBDwsp-1 expressed in a *spd-5(frNAi)* embryo. Movie plays at 60x real time.

Movie 4: Time-lapse movie of GFP::GBDwsp-1 expressed in a *par-2(frNAi)* embryo. Movie plays at 60x real time.

Movie 5: Time-lapse movie of GFP::GBDwsp-1 expressed in a *par-6(zu222)* embryo. Movie plays at 60x real time.

Movie 6: Time-lapse movie of GFP::GBDwsp-1 expressed in an embryo coexpressing CDC-42(Q61L). Movie plays at 60x real time.

Movie 7: Time-lapse movie of GFP::GBDwsp-1 expressed in a *cgef-1(gk261)* embryo. Movie plays at 60x real time.

Movie 8: Time-lapse movie of GFP::GBDwsp-1 expressed in a *chin-1(tm1909)* embryo. Movie plays at 60x real time.

Movie 9: Time-lapse movie of GFP::PAR-6 expressed in a no-RNAi control embryo. Movie plays at 60x real time.

Movie 10: Time-lapse movie of GFP::PAR-6 expressed in a *cgef-1(gk261)* embryo. Movie plays at 60x real time.

Movie 11: Time-lapse movie of GFP::PAR-2 expressed in a no-RNAi control embryo. Movie plays at 60x real time.

Movie 12: Time-lapse movie of GFP::PAR-2 expressed in a *cgef-1(gk261)* embryo. Movie plays at 60x real time.

Movie 13: Time-lapse movie of GFP::CHIN-1 expressed in a no-RNAi control embryo. Movie plays at 60x real time.

Movie 14: Time-lapse movie of GFP::CHIN-1 expressed in a *cdc-42(frNAi)* embryo. Movie plays at 60x real time.

Movie 15: Time-lapse movie of GFP::CHIN-1 expressed in a *par-6(frNAi)* embryo. Movie plays at 60x real time.

Movie 16: Time-lapse movie of GFP::CHIN-1 expressed in a *par-2(frNAi)* embryo. Movie plays at 60x real time.

Movie 17: Time-lapse movie of GFP::CHIN-1 expressed in a *par-1(frNAi)* embryo. Movie plays at 60x real time.

Movie 18: Time-lapse movie of GFP::NMY-2 expressed in a no-RNAi control embryo. Movie plays at 60x real time.

Movie 19: Time-lapse movie of GFP::NMY-2 expressed in a *cgef-1(gk261)* embryo. Movie plays at 60x real time.

Movie 20: Time-lapse movie of GFP::NMY-2 expressed in a *cdc-42(frNAi)* embryo. Movie plays at 60x real time.

Movie 21: Time-lapse movie of GFP::NMY-2 expressed in a *mrck-1(ok586)* embryo. Movie plays at 60x real time.

Movie 22: Time-lapse movie of GFP::NMY-2 expressed in an *ect-2(frNAi)* embryo. Movie plays at 60x real time.

Movie 23: Time-lapse movie of GFP::NMY-2 expressed in a *rho-1(frNAi)* embryo. Movie plays at 60x real time.

Movie 24: Time-lapse movie of GFP::NMY-2 expressed in a *let-502(frNAi)* embryo. Movie plays at 60x real time.

Movie 25: Time-lapse movie of GFP::NMY-2 expressed in a *cdc-42(frNAi); ect-2(frNAi)* embryo. Movie plays at 60x real time.

Supplemental Movie 1: Time-lapse movie of GFP::CDC-42 expressed in a no-RNAi embryo. Movie plays at approximately 60x real time.

Supplemental Movie 2: Time-lapse movie of GFP::CGEF-1A expressed in a no-RNAi embryo. Movie plays at 60x real time.

Supplemental Table 1: Putative *C. elegans* Rho-family-directed GAP- and GEF-encoding genes screened for mislocalization of GFP::*GBDwsp-1*

Genes predicted to encode proteins with RhoGEF domains

| Genetic Name | Molecular Name | RNAi Target | Screen Result | Notes |
|------------------|----------------|-------------|---------------|---|
| cgef-1 / tag-150 | C14A11.3 | both | + | HIT: RNAi embryos exhibit reduced loc at all phases |
| ect-2 | T19E10.1 | genomic | - other | ECT2 (mammalian RhoGEF) homolog; RNAi embryos are hypocontractile |
| tag-77 | C28C12.10 | genomic | - | |
| tag-52 | C02F12.4 | genomic | - | |
| rhgf-2 | T08H4.1 | genomic | - | RHo Guanine nucleotide exchange Factor |
| C11D9.1 | C11D9.1 | genomic | - | |
| uig-1 | F32F2.1 | genomic | - | Unc-112-Interacting Guanine nucleotide exchange factor |
| unc-73 | F55C7.7 | genomic | - | UNCoordinated |
| tag-218 | K07D4.7 | genomic | - | |
| Y105E8A.24 | Y105E8A.24 | cdNA | - | |
| unc-89 | C09D1.1 | genomic | - | UNCoordinated |
| exc-5 | C33D9.1 | genomic | - | EXcretory canal abnormal |
| R02F2.2 | R02F2.2 | genomic | - | |
| Y95B8A.12 | Y95B8A.12 | cdNA | - | |
| gei-18 | Y37A1B.15 | genomic | - | GEX Interacting protein |
| sos-1 | T28F12.3 | genomic | - | Drosophila SOS homolog |
| rhgf-1 | F13E6.6 | cdNA | - | RHo Guanine nucleotide exchange Factor |
| pix-1 | K11E4.4 | --- | no result | PIX Interacting eXchange factor) homolog; no construct for RNAi |

Genes predicted to encode proteins with RhoGAP domains

| Gene Name | Molec Name | construct | Notes | |
|----------------------|-------------|-----------|---------|--|
| chin-1 / BE0003N10.2 | BE0003N10.2 | cdNA | + | HIT: RNAi embryos exhibit abnormal PII and PIII probe loc |
| cyk-4 | K08E3.6 | genomic | - other | CYtoKinesis defect; RNAi embryos fail cytokinesis |
| rga-3 | K09H11.3 | genomic | - other | Rho GTPase Activating protein; RNAi embryos hypercontractile |
| rga-1 | W02B12.8 | genomic | - | Rho GTPase Activating protein |


| | | | | |
|----------|-----------|---------|---|--|
| F23H11.4 | F23H11.4 | genomic | - | OCRL (Lowe's oculocerebrorenal syndrome protein) |
| ocr1-1 | C16C2.3 | genomic | - | homolog |
| srgp-1 | F12F6.5 | genomic | - | Slit-Robo GAP homolog |
| rga-2 | Y53C10A.4 | genomic | - | Rho GTPase Activating protein |
| hum-7 | F56A6.2 | genomic | - | Heavy chain, Unconventional Myosin |
| rlbp-1 | T23G11.5 | genomic | - | RaL Binding Protein |
| Y34B4A.8 | Y34B4A.8 | cdna | - | |
| C01F4.2 | C01F4.2 | genomic | - | |
| gei-1 | F45H7.2 | genomic | - | |
| rga-4 | Y75B7AL.4 | cdna | - | Rho GTPase Activating protein |
| T04C9.1 | T04C9.1 | genomic | - | |
| tag-341 | ZK669.1 | genomic | - | |
| 2RSSE.1 | 2RSSE.1 | cdna | - | |
| pac-1 | C04D8.1 | genomic | - | PAR-6 At Contacts (abnormal early localization of PAR-6) |
| syd-1 | F35D2.5 | genomic | - | SYnapse Defective |
| tag-325 | C38D4.5 | genomic | - | |
| rrc-1 | F47A4.3 | genomic | - | RhoGAP for Rac-1 and Cdc-42 |
| H08M01.2 | H08M01.2 | genomic | - | |

Supplemental Table 2: Genetic interactions of *candidate GEF(RNAi)* with *cgef-1(gk261)*

| | Brood size (N2) | Brood size (WH514) | Embryonic Survival (N2) | +/- SEM | Embryonic Survival (WH514) | +/- SEM | p-value for RNAi alone | p-value for interaction |
|-------------------|-----------------|--------------------|-------------------------|---------|----------------------------|---------|------------------------|-------------------------|
| none | 211 | 226 | 99.6% | 0.4% | 98.8% | 0.7% | | |
| <i>tag-52</i> | 274 | 175 | 99.6% | 0.4% | 89.7% | 2.3% | | |
| <i>tag-127</i> | 236 | 170 | 100.0% | 0.0% | 67.0% | 3.6% | * | * |
| <i>C11D9.1</i> | 354 | 234 | 99.7% | 0.3% | 86.3% | 2.2% | | 0.015 |
| <i>uig-1</i> | 211 | 307 | 100.0% | 0.0% | 98.0% | 0.8% | * | * |
| <i>unc-73</i> | 227 | 270 | 99.6% | 0.4% | 96.7% | 1.1% | | |
| <i>tag-218</i> | 311 | 235 | 99.0% | 0.6% | 98.3% | 0.8% | | |
| <i>Y105E8A.24</i> | 185 | 200 | 98.9% | 0.8% | 91.5% | 2.0% | | |
| <i>unc-89</i> | 240 | 257 | 99.2% | 0.6% | 98.8% | 0.7% | | |
| <i>exc-5</i> | 262 | 255 | 98.5% | 0.8% | 99.2% | 0.6% | 0.048 | |
| <i>R02F2.2</i> | 93 | 164 | 95.7% | 2.1% | 66.4% | 3.7% | 0.001 | |
| <i>Y95B8A.12</i> | 247 | 222 | 98.4% | 0.8% | 87.8% | 2.2% | 0.040 | |
| <i>gei-18</i> | 315 | 171 | 98.4% | 0.7% | 96.5% | 1.4% | 0.032 | |
| <i>sos-1</i> | 319 | 237 | 97.5% | 0.9% | 96.6% | 1.2% | 0.002 | |
| <i>rhgf-1</i> | 265 | 253 | 97.4% | 1.0% | 99.2% | 0.6% | 0.002 | 0.014 |
| <i>tag-77</i> | 326 | 181 | 98.2% | 0.7% | 94.5% | 1.7% | 0.014 | |

Brood size and embryonic survival from N2[*wild-type*] or WH514[*cgef-1(gk261)*] animals either untreated or treated with fRNAi directed at the indicated gene. Effects on embryonic survival of the depletion condition and of the interaction of the depletion condition with the *cgef-1(gk261)* genotype were investigated by logistic regression analysis. If statistically significant, the p-values of either parameter are presented above. Asterisks indicate that the p-value is uninformative due to the absence of observed dead embryos in the depletions of wild-type embryos of those conditions. Each tested condition was represented by at least two worms.

Supplemental Figure 1




Supplemental Figure 2


GFP::CDC-42

GFP::CDC-42(T17N)


GFP::CDC-42(Q61L)



Supplemental Figure 3



Supplemental Figure 4
Observed maximum speeds of GFP::NMY-2-labeled
cortical regions during phase I



Supplemental Figure 5

